Founder and Chief Executive Officer
Mr. Legorreta founded Royalty Pharma in 1996, after creating and managing two “proof of principle” investment vehicles in 1993 and 1994 that invested in royalty interests in two leading biotechnology products. Prior to founding these investment vehicles, Mr. Legorreta spent ten years at Lazard Frères where he provided cross-border merger and acquisition and corporate finance advisory services to US and European corporations. Mr. Legorreta joined Lazard Frères et Cie in Paris in 1988, then moved to Lazard Frères & Co in New York in 1990. Mr. Legorreta currently serves as a Director of Giuliani, Médica Sur, as well as a member of the Board of Trustees of The Allen-Stevenson School, the Park Avenue Armory and of the American-Austrian Foundation/Open Medical Institute. Mr. Legorreta founded and is currently Chairman the Board of Trustees of the Alianza Médica para la Salud, a privately-funded, not-for-profit foundation whose goal is to educate Mexican physicians and healthcare providers in order to improve the quality of Mexican and Latin American healthcare. Mr. Legorreta received a degree in industrial engineering from Universidad Iberoamericana.
Executive Vice President and Chief Financial Officer
Ms. Gray joined Royalty Pharma in January 2005 after a fourteen year career in investment banking. At Royalty Pharma, Ms. Gray has led the Company’s efforts to maximize its financial capabilities. She spearheaded the Company’s successful implementation of a $2.3 billion credit facility in 2007 and has helped raise over $1.4 billion in equity capital for the Company. Ms. Gray was a managing director and the senior analyst covering the healthcare sector for CIBC World Market's high yield group from 2002 to 2004. She worked in a similar capacity at Merrill Lynch prior to joining CIBC World Markets. Ms. Gray joined Merrill Lynch in April 1999 after nine years at Chase Securities (a predecessor of JP Morgan), working in various capacities within the high yield and the structured finance groups. Ms. Gray received a BA with honors from Wesleyan University and holds an MBA degree from Columbia University.
Executive Vice President
RP (CA) Advisors, LLC
Mr. Kwit joined Royalty Pharma in 2001. Since that time, he has been at the forefront of structuring and negotiating biopharmaceutical royalty transactions. He has closed over $3.2 billion in royalty acquisitions, including Royalty Pharma’s $700 million acquisition of the Lyrica® royalty and the $700 million acquisition of the Humira® royalty. He has also been integrally involved in structuring Royalty Pharma’s novel financing programs, including the first ever asset-based securitization of biopharmaceutical royalties in 2003 and the company’s $2.3 billion senior secured credit facility. From 2000 to 2001, Mr. Kwit served as Vice President of Business Affairs, and General Counsel, for a New York based digital media entertainment company. From 1996 to 2000, Mr. Kwit was an Associate at Davis, Polk & Wardwell, where he specialized in mergers & acquisitions and securities law, representing several Fortune 100 and other companies. Mr. Kwit received a BA from Duke University, where he was elected to Phi Beta Kappa, and holds a JD degree from Columbia University Law School, where he was a Harlan Fiske Stone Scholar. He has been a member of the New York State Bar Association since 1997.
Jim Reddoch, PhD
Executive Vice President, Head of Research & Investments
Dr. Reddoch joined Royalty Pharma in July 2008 after twelve years on Wall Street as a biotechnology analyst. Prior to joining Royalty Pharma, Dr. Reddoch was Managing Director and Head of Healthcare Equity Research at Friedman Billings Ramsey. He previously worked at Bank of America and CIBC World Markets Corp (now Oppenheimer & Co). Dr. Reddoch holds a BA from Furman University and a PhD in biochemistry and molecular genetics from the University of Alabama at Birmingham. He was a postdoctoral fellow at the Yale University School of Medicine.
Executive Vice President, Investments
Prior to joining Royalty Pharma, Mr. Lloyd was a partner in Goodwin Procter LLP’s Private Equity Group. Prior to Goodwin Procter, Mr. Lloyd was a partner at Testa Hurwitz & Thibeault LLP, where he was co-head of the mergers & acquisitions group, and an associate at Davis Polk & Wardwell LLP, where he was in the mergers & acquisitions group. Mr. Lloyd’s legal practice focused on public and private mergers and acquisitions, leveraged buyouts, leveraged recapitalizations, venture capital financing, mezzanine lending, public offerings, public and private high yield offerings, and general corporate representation for private equity firms, public and private corporations, entrepreneurs and investment banks. In 2002-2003, Mr. Lloyd worked in Hong Kong as the Chief Financial Officer and General Counsel of the Asian operations of one of his clients. Mr. Lloyd received an AB from Princeton University and a JD degree from New York University Law School, where he was on the Law Review.
Molly Chiaramonte, PhD
Vice President, Research & Investments
Dr. Chiaramonte joined Royalty Pharma in January 2008. From 2006 to 2008, Dr. Chiaramonte worked as a biotechnology equity research associate at Jefferies & Company. From 2002 to 2006, she was a post-doctoral fellow in the Department of Biochemistry and Molecular Genetics at the University of Colorado Health Sciences Center. Dr. Chiaramonte received a BA in mathematics, summa cum laude, from Providence College; an MA in mathematics from the University of Colorado; and a PhD in chemistry (Biochemistry Program) from the University of Colorado.
Vice President, Research & Investments
Mr. Coyne joined Royalty Pharma in 2010. Prior to joining Royalty Pharma, Mr. Coyne worked as a biotechnology equity research associate, and most recently as a senior analyst at JP Morgan from 2007 to 2010. From 2006 to 2007, he worked as a biotechnology equity research associate at Rodman & Renshaw. Prior to this, Mr. Coyne worked in various commercial roles at Wyeth Pharmaceuticals. Mr. Coyne received a BS in business administration from La Salle University and an MBA from La Salle University.
James S. Rielly
Vice President, Finance
Mr. Rielly joined Royalty Pharma in 1999. From December 1997 to May 1999, Mr. Rielly was the Vice President of Finance, Treasurer and Secretary of Cadus Pharmaceutical Corporation, a publicly traded biotechnology company. Mr. Rielly joined Cadus Pharmaceutical Corporation as its Controller in September 1992. From November 1989 to September 1992, Mr. Rielly was the Controller and Treasurer for Baring Brothers & Company Ltd, an investment banking firm. Mr. Rielly is a certified public accountant and holds a BSBA from Bucknell University.
Alexander von Perfall
Vice President, Investor Relations & Public Affairs
Mr. von Perfall joined Royalty Pharma in 2009. Prior to joining Royalty Pharma, Mr. von Perfall was the Co-Founder and Chief Network Officer of XTF, a start-up exchange traded fund ratings agency. Mr. von Perfall started his career as a talent scout with BMG Entertainment where he oversaw the artistic development of a number of critically and commercially successful recording artists, followed by corporate venturing positions with Bertelsmann AG where he initiated and oversaw early stage investments in IP based media and entertainment companies. Following Bertelsmann, Mr. von Perfall served in an advisory role for the International Finance Corporation/World Bank Group where he acted as value proposition expert for the syndication of media sector investments. Mr. von Perfall attended the Hochschule St. Gallen in Switzerland and holds a BA in politics from the University of San Francisco and an MBA from the Stern School of Business at New York University.
Associate, Research & Investments
Ms. Zhang joined Royalty Pharma in 2008. Ms. Zhang received a BS with honors in genetics from the University of Manitoba. She is a CFA (Chartered Financial Analyst) Level III Candidate.
Analyst, Research & Investments
Ms. Klymkowsky joined Royalty Pharma in 2012. Prior to joining Royalty Pharma, Ms. Klymkowsky was an Analyst in the Healthcare Investment Banking group at Goldman, Sachs & Co in New York. Ms. Klymkowsky holds a BA in Molecular, Cellular and Developmental Biology and a BSBA from the University of Colorado at Boulder.